August Wrap-up; New Stocks in biotech, transportation, tech, mining and defense; (Nasdaq: $QNTM) (Nasdaq: $ELEV) (NYSE American: $OSTX) (NYSE: $DAL) (Nasdaq: $SNCY) (NYSE: $LUMN) (TSXV: $FAS) (NYSE: $PRM)

 August Wrap-up; New Stocks in biotech, transportation, tech, mining and defense; (Nasdaq: $QNTM) (Nasdaq: $ELEV) (NYSE American: $OSTX) (NYSE: $DAL) (Nasdaq: $SNCY) (NYSE: $LUMN) (TSXV: $FAS) (NYSE: $PRM) 

 

 

 

 

August 30, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the biotech, transportation, tech, mining and defense sectors.

 

The newest biotech companies treat neurodegenerative and metabolic disorders and cancers respectively.

 

The latest transportation companies are airlines, while the newest tech company provides telecom and related services.

 

The latest mining company mines for silver in Peru and the newest defense company provides Fire Safety and Specialty Products.

 

Read this in full at https://www.investorideas.com/news/2024/main/08301Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Biotech Directories:

Quantum BioPharma Ltd (Nasdaq:QNTM; CSE:QNTM) - Formerly FSD Pharma Inc - is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma invented unbuzzd™ and spun it out its OTC version to a company, Celly Nutrition, led by industry veterans. FSD retains ownership of 25.71% (March 31, 2024) of Celly Nutrition Corp. at www.cellynutrition.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd ™ until payments to FSD Pharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, FSD Pharma retains a large tax loss carry forward of approximately CAD$130 million and could be utilized in the future to offset tax payable obligations against future profits. FSD Pharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical / medical uses. FSD Pharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.

 

Elevation Oncology, Inc. (Nasdaq: ELEV) is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC designed to target Claudin 18.2 and is currently being evaluated in a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024.

 

OS Therapies, Inc. (NYSE American:OSTX) is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker technology, enabling the delivery of multiple payloads per linker.

 

New Stocks Added to the Transportation Directories:

Delta Air Lines, Inc. (NYSE:DAL) Headquartered in Atlanta, Delta operates significant hubs and key markets in Amsterdam, Atlanta, Bogota, Boston, Detroit, Lima, London-Heathrow, Los Angeles, Mexico City, Minneapolis-St. Paul, New York-JFK and LaGuardia, Paris-Charles de Gaulle, Salt Lake City, Santiago (Chile), Sao Paulo, Seattle, Seoul-Incheon and Tokyo.

As the leading global airline, Delta's mission to connect the world creates opportunities, fosters understanding and expands horizons by connecting people and communities to each other and to their own potential. Powered by innovative and strategic partnerships with Aeromexico, Air France-KLM, China Eastern, Korean Air, LATAM, Virgin Atlantic and WestJet, Delta brings more choice and competition to customers worldwide. Delta's premium product line is elevated by its unique partnership with Wheels Up Experience. Delta is America's most-awarded airline thanks to the dedication, passion and professionalism of its people. In addition to the awards from J.D. Power and Cirium, Delta has been recognized as the top U.S. airline by the Wall Street Journal; among Fast Company's Most Innovative Companies; the World's Most Admired Airline and one of the Best 100 Companies to Work For according to Fortune; and as one of Glassdoor's Best Places to Work. In addition, Delta has been named to the Civic 50 by Points of Light for the past seven years as one of the most community minded companies in the U.S.

 

Sun Country Airlines Holdings, Inc. (Nasdaq: SNCY) is a new breed of hybrid low-cost air carrier, whose mission is to connect guests to their favorite people and places, to create lifelong memories and transformative experiences. Sun Country dynamically deploys shared resources across our synergistic scheduled service, charter, and cargo businesses. Based in Minnesota, we focus on serving leisure and visiting friends and relatives (“VFR”) passengers and charter customers and providing cargo service to Amazon, with flights throughout the United States and to destinations in Mexico, Central America, Canada, and the Caribbean.

 

New Stocks Added to the Tech Directories:

Lumen Technologies (NYSE: LUMN) connects the world. We are igniting business growth by connecting people, data, and applications – quickly, securely, and effortlessly. Everything we do at Lumen takes advantage of our network strength. From metro connectivity to long-haul data transport to our edge cloud, security, and managed service capabilities, we meet our customers' needs today and as they build for tomorrow.

 

New Stocks Added to the Mining Directories:

FIRST ANDES SILVER LTD. (TSXV: FAS) (OTC Pink: MSLVF) (FSE: 9TZ) is a British Columbia company that holds a 100% interest in the high-grade Santas Gloria silver property, located in Peru.

 

New Stocks Added to the Defense Directories:

Perimeter Solutions, SA (NYSE: PRM)  is a leading global solutions provider, providing high-quality firefighting products and phosphorus-based specialty chemicals. The Company's business is organized and managed in two reporting segments: Fire Safety and Specialty Products. The Fire Safety business consists of formulating, manufacture and sale of fire retardants and firefighting foams that assist in combating various types of fires, including wildland, structural, flammable liquids and others. Our Fire Safety business also offers specialized equipment and services, typically in conjunction with our fire management products, to support our customers' firefighting operations. Our specialized equipment includes airbase retardant storage, mixing, and delivery equipment; mobile retardant bases; retardant ground application units; mobile foam equipment; and equipment that we custom design and manufacture to meet specific customer needs. Our service network can meet the emergency resupply needs of over 150 air tanker bases in North America, as well as many other customer locations in North America and internationally. The segment is built on the premise of superior technology, exceptional responsiveness to our customers' needs, and a "never-fail" service network. The segment sells products to government agencies and commercial customers around the world. The Specialty Products business produces and sells high quality Phosphorus Pentasulfide ("P2S5") primarily used in the preparation of lubricant additives, including a family of compounds called Zinc Dialkyldithiophosphates ("ZDDP") that provide critical anti-wear protection to engine components. P2S5 is also used in pesticide and mining chemicals applications.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

 

The GLP-1 Products and Players –Stocks to Watch

 

The GLP-1 Products and Players –Stocks to Watch

 

Stocks mentioned- Integrated Ventures, Inc. (OTCQB: $INTV), Novo Nordisk (NYSE: $NVO), Eli Lilly and Company (NYSE: $LLY), Hims & Hers Health, Inc., (NYSE: $HIMS), Viking Therapeutics, Inc. (NASDAQ: $VKTX)

 

August 28, 2024 - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot looking at news and developments for the global GLP-1 receptor agonist market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV).

 

According to Research and Markets, The global GLP-1 receptor agonist market size is expanding at a CAGR of 21.65% from 2024 to 2030”

 

Continued: “The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk (NYSE: NVO), which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.”

 

“Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company (NYSE: LLY) entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai's proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.”

 

Continued: “The Novo Nordisk A/S (NYSE: NVO) Ozempic segment dominated the market and accounted for a share of 37.77% in 2023. Ozempic is a brand-name U.S. FDA-approved prescription drug used to treat adults with type 2 diabetes.”

 

Today, Integrated Ventures, Inc. (OTCQB: INTV) announced its strategic entry into the rapidly expanding health and wellness sector.

 

The initial phase of this transition will be led by the newly established subsidiary, MedWell USA, LLC, which will serve as a B2B Procurement Agent for a variety of pharmaceutical products, with a particular focus on the booming medical weight loss and GLP-1 markets.

 

MedWell USA will be focused on the development of innovative weight loss and wellness management solutions, targeting B2B clients such as medical offices, fitness facilities and wellness clinics. This approach is designed to meet emerging consumer demands and capitalize on the significant growth within the global health and wellness industry.

 

Paid news dissemination for INTV

 

Read this news, featuring INTV in full at https://www.investorideas.com/news/2024/biotech/08281GLP-1-Products-and-Players.asp

 

Steve Rubakh, CEO of Integrated Ventures, comments: “This strategic entry represents a significant evolution for our company. The health and wellness sector offers immense growth potential, and we are eager to bring unique and impactful solutions (B2B and B2C) to market that will meet the critical needs of consumers seeking to improve their health and well-being. According to UB Securities (*) forecast, the combined GLP-1 market for obesity and diabetes will reach $129 billion by 2029, with 40 million users (with 44% based in USA) and a robust compound annual growth rate (CAGR) of 30%.”

(*) https://www.ubs.com/global/en/investment-bank/in-focus/2024/glp-1-a-medication.html

 

In addition to launching MedWell USA, the Company is in the process of establishing two more subsidiaries aimed at broadening its weight loss related operations. Furthermore, the Company is finalizing strategic joint ventures that will enable INTV to quickly and effectively penetrate the lucrative health and wellness market.

 

Integrated Ventures is committed to driving shareholder value by seizing high-growth opportunities within the health and wellness sector. The Company will provide regular updates as it advances its strategic plans and achieves key milestones.

 

In May, Hims & Hers Health, Inc., (NYSE: HIMS) the leading health and wellness platform,  announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving customers an affordable way to consistently access safe, high-quality weight loss treatment.

 

From the news: The company now offers access to GLP-1 injections in addition to weight management oral medication kits, so that customers can truly personalize their weight loss experience. Providing access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic® and Wegovy® without navigating the shortages and costs that are currently limiting access to the branded medications. Through a partnership with a leading US manufacturer of generic and 503B compounded injectable medications, Hims & Hers can help millions of Americans who have obesity and are looking for help safely managing their weight.

 

"The core of our business is to offer a truly personalized experience that customers can trust and rely on," said Andrew Dudum, CEO and co-founder of Hims & Hers. "We’ve leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today. We’re passing that access and value along to our customers, who deserve the highest standard of clinical safety and efficacy to meet their goals, and we're doing it in a safe, affordable way that others can’t deliver."

 

Continued: According to the US Food and Drug Administration (FDA), around 70% of American adults have obesity or are overweight, and losing 5 to 10% of that body weight can reduce weight-related health risks, such as diabetes and cardiovascular disease. GLP-1 medications can support healthy weight loss along with a reduced calorie diet and increased exercise by helping manage blood sugar levels, curb cravings and suppress appetite, so people eat less without feeling deprived.

 

In June, Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.  The presentation highlighted the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide.  The studies were summarized in a poster presentation at the annual scientific conference of the American Diabetes Association, held in Orlando, Florida in June of this year,

 

From the news: The study results demonstrate that Viking's series of dual amylin and calcitonin receptor agonists (DACRAs) reduced food intake in lean rats in the period from 0 – 72 hours following a single subcutaneous dosing.  At 72 hours following a single subcutaneous dose, Viking's novel compounds resulted in up to 8% body weight reductions compared to vehicle-treated animals.

 

Continued: In a DIO mouse model, treatment with Viking's series of co-agonists for 24 days resulted in body weight reductions that were comparable to those achieved in cagrilintide-treated animals.  Additionally, improvements in key metabolic markers, including blood glucose levels, were observed in DIO mice treated with the company's compounds for the 24-day time period.

 

Looking at the future for the sector, Research and Markets notes, “The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk (NYSE: NVO) is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.”

 

Continued: “The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA and others for the existing products to increase their life cycle.”

 

Research and find more biotech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

 

Research health and wellness stocks at Investorideas.com

https://www.investorideas.com/LOHAS-investing/Stock_List.asp

 

About Investorideas.com

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

 

Disclaimer/Disclosure: This news article featuring - Integrated Ventures, Inc. (OTCQB: INTV) is a paid for news release creation and dissemination on Investorideas.com.  Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

 

Health, wellness and sustainability stocks - Get more HWS news, articles and stock directories

Trinity Biotech plc (Nasdaq: TRIB) Spikes on Orders for TrinScreen HIV

Trinity Biotech plc (Nasdaq: TRIB) Spikes on Orders for TrinScreen HIV: Trinity Biotech plc (Nasdaq: TRIB) Spikes on Orders for TrinScreen HIV

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

 

Results Support Future Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Association with Function of Retrieved Kidneys

 

SAN DIEGO, CA - August 27, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication in preprint of an in vitro study in bioRxiv on August 24, 2024, entitled, "The Hemopurifier® Removes Extracellular Vesicles and microRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys."

 

Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids, qualities which have potential applications in oncology and infectious diseases, as well as in the organ transplant setting.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical Inc.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/08271AEMD-Hemopurifier-Preclinical-data.asp

"Kidney transplantation provides the highest quality of life for those afflicted with end stage renal disease, yet a significant shortage in the number of donor kidneys currently exists," stated Steven LaRosa, MD, Senior Author of the paper and Chief Medical Officer of Aethlon Medical. "To bridge the gap between recipients and donors, the criteria for the use of kidneys from deceased brain death and diseased circulatory death donors has been extended. However, kidneys from extended criteria donors are associated with higher rates of poor graft function and acute rejection in recipients. The release of extracellular vesicles (EVs) and microRNAs from the donor kidney are hypothesized to play a role in these complications and are targets for the, Hemopurifier®."

 

Given that one approach to lessen these complications and potentially increase the time of assessment of organ viability is to use machine perfusion on recovered kidneys, and, based on Aethlon Medical's prior data in COVID-19 and oncology, it was hypothesized that the Hemopurifier® could remove EVs and microRNAs from renal perfusates. In this proof-of-concept study, the company obtained four perfusates from discarded donor kidneys that had undergone a type of machine perfusion called Controlled Oxygenated Rewarming (COR). These perfusates were then pumped over the Hemopurifier® and analyzed for EV counts and microRNA levels. The results confirmed the removal of both small and larger size EVs and a significant reduction in microRNAs.

 

"While our primary focus is to conduct our planned clinical trials of the Hemopurifier® in India and Australia, in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy, the data generated by this proof-of-concept study is encouraging and provides evidence for adding the transplant indication to our product pipeline," added James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "Next steps to consider would be an additional pre-clinical study comparing mediator removal, renal function and histopathology in a machine perfusion circuit performed both with and without incorporation of the Hemopurifier® on discarded kidneys.

Ultimately, a clinical trial designed to demonstrate that incorporation of the Hemopurifier® into renal perfusion improves important clinical endpoints in transplant recipients such as delayed graft function, graft survival or rejection rates would likely be required."

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company's ability to initiate its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the potential impact of Hemopurifier on the H5N1 Avian Influenza (H5N1 HPAI) virus in dairy cattle; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303

 

SOURCE Aethlon Medical, Inc.

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories